Burns

🩺What is Burns?

Body Surface Area (BSA) is a calculated measurement of the external surface area of the human body, expressed in square meters (m²). The concept was first formalized by Du Bois and Du Bois in 1916, who developed the first widely accepted formula using nine anatomical measurements. BSA is commonly used in clinical practice for normalizing physiological parameters — including cardiac output indexed as cardiac index (CI = CO/BSA), calculating chemotherapy doses (most cytotoxic agents are dosed per m²), assessing burn severity using the Rule of Nines and Lund-Browder chart, and determining glucocorticoid replacement doses. The reference standard value of 1.73 m² is used for indexing renal function (eGFR is normalized to 1.73 m²). Multiple formulas have been developed over the past century, with Mosteller (1987) being the most widely used today due to its simplicity and ease of bedside calculation. The choice of formula may affect dosing by 10–20% at extremes of body size, so consistency within institutions is important. The evidence level for BSA estimation is Grade B, supported by extensive physiological validation studies but limited by the absence of a true gold standard for surface measurement.

📊Clinical Assessment & Risk Scoring

Healthcare professionals use these validated clinical calculators, diagnostic scales, and risk scoring systems to assess the severity, prognosis, or therapeutic dosing requirements for Burns:

• Body Surface Area Calculator

  Body Surface Area (BSA) is a measurement of the total surface area of the human body used in many medical contexts including chemotherapy dosing, cardiac output indexing, and burn management.

🧬Diagnostic Logic & Scoring Breakdown

The Mosteller formula is calculated as the square root of (height in cm × weight in kg) / 3600. For example, a patient weighing 70 kg and measuring 175 cm has BSA = √(175 × 70 / 3600) = √(12250 / 3600) = √3.403 = 1.84 m². The DuBois-DuBois formula (1916) is BSA = 0.007184 × W^0.425 × H^0.725, which was derived from direct anatomical measurements of only 9 subjects. The Boyd formula (1935) uses BSA = 0.0003207 × H^0.3 × (W × 1000)^(0.7285 − 0.0188 × log(W × 1000)) and was derived from a larger sample. The Haycock formula (1978) uses BSA = 0.024265 × W^0.5378 × H^0.3964 and was developed specifically for pediatric populations. Each formula yields slightly different results, with discrepancies of up to 10–15% at extremes of body weight. In clinical practice, the Mosteller formula is preferred for its simplicity and sufficient accuracy. To interpret BSA, values are compared against known population norms: the average adult BSA is approximately 1.73 m². Chemotherapy doses are calculated as Dose = Published Dose × (Patient BSA / 1.73). Burn severity uses BSA percent involvement, where >20% BSA in adults constitutes major burns requiring referral to a burn center.

📢Clinical Significance & Implications

BSA is one of the most important anthropometric measurements in clinical medicine with applications across multiple specialties. In oncology, the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) recommend BSA-based dosing for the majority of cytotoxic chemotherapy agents, as this approach reduces inter-individual variability in drug exposure. For carboplatin, the Calvert formula uses BSA along with renal function to calculate the optimal dose. In cardiology, cardiac output is indexed to BSA as cardiac index (normal: 2.5–4.0 L/min/m²), which is essential for classifying heart failure severity and guiding therapy. In nephrology, the estimated glomerular filtration rate (eGFR) reported by all laboratories is normalized to a standard BSA of 1.73 m², allowing comparison across individuals of different body sizes. In burn management, the total body surface area (TBSA) of burn involvement, estimated using the Rule of Nines or Lund-Browder chart, determines fluid resuscitation requirements via the Parkland formula (4 mL × TBSA% × weight) and guides transfer decisions to burn centers. The American Burn Association recommends that burns involving >10% TBSA in patients under 50 or >5% in patients over 50 be referred to specialized centers. BSA also guides dosing of certain medications including acyclovir, aminoglycosides, and antifungals in some protocols. Despite its broad utility, BSA-based dosing has limitations — it does not account for differences in drug metabolism, organ function, or body composition, which has led to a shift toward therapeutic drug monitoring where feasible.

💡 Clinical Assessment Scenario Example

A 58-year-old woman with newly diagnosed stage III ovarian cancer is being evaluated for first-line chemotherapy with carboplatin and paclitaxel. Her current weight is 68 kg and her height is 160 cm. Her oncologist needs to calculate her BSA to determine the appropriate chemotherapy doses. Using the Mosteller formula: BSA = √(height in cm × weight in kg / 3600) = √(160 × 68 / 3600) = √(10880 / 3600) = √3.022 = 1.74 m². For comparison, the DuBois formula gives: BSA = 0.007184 × 68^0.425 × 160^0.725 = 0.007184 × 5.84 × 39.81 = 0.007184 × 232.5 = 1.67 m². The difference between formulas is approximately 4%, which is acceptable for clinical purposes. The patient's BSA of 1.74 m² is close to the standard reference of 1.73 m². For carboplatin dosing, her target AUC (area under the curve) of 5–6 mg/mL/min will be used with the Calvert formula: Dose = Target AUC × (GFR + 25). Her calculated creatinine clearance using Cockcroft-Gault is 78 mL/min. Carboplatin dose = 5 × (78 + 25) = 515 mg. For paclitaxel, the standard dose of 175 mg/m² is used: 175 × 1.74 = 305 mg. The patient's BSA also indicates she has a normal body habitus, and the standard dosing protocol applies without adjustment. Monthly monitoring of blood counts and renal function is planned to assess for chemotherapy-related toxicity.

💊Common Medications & Interventions

The following pharmacological therapies and substances are commonly referenced or adjusted based on the clinical assessment of Burns:

🔗Related Diseases & Conditions

These conditions are clinically associated with Burns through shared risk-scoring calculators and assessment tools:

• Obesity
• Cachexia

⚠️Clinical Assessment Pitfalls

• ❌ Mistake: Using different BSA formulas interchangeably for chemotherapy dosing

  ✅ Correction: Mosteller formula is the current standard. Converting between formulas can lead to dose discrepancies at extremes of body size.

• ❌ Mistake: Using BSA for drug dosing in obese patients without adjustment

  ✅ Correction: Consider using adjusted ideal body weight or lean body weight for chemotherapy dosing in obese patients — see ASCO guidelines.

• ❌ Mistake: Using BSA-based cardiac index in very large or very small patients

  ✅ Correction: BSA-based indexing may overcorrect in extremely obese or underweight individuals. Consider alternative normalization methods.

• ❌ Mistake: Applying burn BSA estimation formulas in obese patients without adjustment

  ✅ Correction: The Rule of Nines overestimates burn size in obesity. Use the Lund-Browder chart which accounts for body habitus, or adjust using patient-specific nomograms.

• ❌ Mistake: Using BSA for pediatric patients without age-specific formulas

  ✅ Correction: For children, the Mosteller formula is valid but the Haycock or Boyd formulas may be more accurate. Pediatric chemotherapy protocols should specify which BSA formula was used in the original trial.

🚑When to Seek Medical Attention

This reference supports clinical assessment of Burns; it does not replace urgent evaluation. Seek prompt in-person medical care if symptoms are severe, rapidly worsening, or life-threatening, or if you are unsure about a diagnosis or treatment plan. Patients should always consult their physician before starting or changing any therapy.

❓Frequently Asked Questions

📚Evidence-Based References